Taiwan Resonant Waves Research Corp. (TRWR), a Taiwan-based bioelectronic medicines company with global healthcare perspective, aims to offer patients better health care options with innovative complementary therapy solutions to treat metabolic, immune, and neurological related chronic diseases. This novel treatment involves the use of a non-invasive and portable microcurrent electrical nerve stimulation device to deliver mild electrical impulse stimulations in specific proprietary frequency combinations to the human body to complementary treat different chronic diseases.

TRWR Type 2 Diabetes Bioelectronic Medicine: Currently undergoing regulatory market approval review by Taiwan FDA as a new medical device with no predicate in the world with indication of glycemic variability reduction.
TRWR Type 1 Diabetes Bioelectronic Medicine: Completed pre-clinical validation on disease onset delay with mechanism of therapeutic action studies in progress.
TRWR Pain Bioelectronic Medicine: Obtained class II medical device market approval from Taiwan FDA as “Dragon Waves Resonant Home Care” Electronic Nerve Stimulator.
TRWR Sleep Disorder Bioelectronic Medicine: Completed pilot clinical trials for sleep quality improvement and obstructive sleep apnea treatment.

We are actively looking for strategic partnership opportunities to accelerate the commercialization of our treatments in the global market.